N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway
- PMID: 35528507
- PMCID: PMC9068303
- DOI: 10.1155/2022/8123120
N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway
Abstract
Breast cancer is of the leading causes of cancer-related deaths and the most frequently diagnosed cancer among females worldwide. Despite advancements in breast cancer therapy, the disease eventually progresses in most patients because of de novo or secondary resistance. Thus, discovering novel drugs with high effectiveness and low toxicity for systemic therapy is essential. In this study, we investigated whether a new oleanolic derivative N-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide (ZQL-4c) exhibits potential anticancer effects against breast cancer. We determined that ZQL-4c strongly inhibited cell proliferation and invasion and induced G2/M phase arrest and apoptosis in breast cancer cells. We then found that ZQL-4c induced the production of reactive oxygen species (ROS). We then found that ZQL-4c significantly inhibited Notch-AKT signaling pathways that are related to oxidative stress. Taken together, this study is the first to show that ZQL-4c can significantly suppress the growth and invasion of breast cancer by blocking Notch-Akt signaling pathways, which are mainly regulated by ROS-mediated oxidative stress. Thus, ZQL-4c might be considered a novel and potential anticancer drug for breast cancer treatment.
Copyright © 2022 Xiaorui Li et al.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Chrysophanol selectively represses breast cancer cell growth by inducing reactive oxygen species production and endoplasmic reticulum stress via AKT and mitogen-activated protein kinase signal pathways.Toxicol Appl Pharmacol. 2018 Dec 1;360:201-211. doi: 10.1016/j.taap.2018.10.010. Epub 2018 Oct 6. Toxicol Appl Pharmacol. 2018. PMID: 30300626
-
Ambrosin sesquiterpene lactone exerts selective and potent anticancer effects in drug-resistant human breast cancer cells (MDA-MB-231) through mitochondrial mediated apoptosis, ROS generation and targeting Akt/β-Catenin signaling pathway.J BUON. 2020 Sep-Oct;25(5):2221-2227. J BUON. 2020. PMID: 33277839
-
Triazole analog 1-(1-benzyl-5-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)-2-(4-bromophenylamino)-1-(4-chlorophenyl)ethanol induces reactive oxygen species and autophagy-dependent apoptosis in both in vitro and in vivo breast cancer models.Int J Biochem Cell Biol. 2015 Aug;65:275-87. doi: 10.1016/j.biocel.2015.06.016. Epub 2015 Jun 24. Int J Biochem Cell Biol. 2015. PMID: 26115963
-
MICAL1 controls cell invasive phenotype via regulating oxidative stress in breast cancer cells.BMC Cancer. 2016 Jul 18;16:489. doi: 10.1186/s12885-016-2553-1. BMC Cancer. 2016. PMID: 27430308 Free PMC article.
-
Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway.ChemMedChem. 2016 Oct 19;11(20):2339-2346. doi: 10.1002/cmdc.201600261. Epub 2016 Sep 28. ChemMedChem. 2016. PMID: 27677422
Cited by
-
Notch signaling, hypoxia, and cancer.Front Oncol. 2023 Jan 31;13:1078768. doi: 10.3389/fonc.2023.1078768. eCollection 2023. Front Oncol. 2023. PMID: 36798826 Free PMC article. Review.
References
-
- Wu C., Qiu S., Liu P., Ge Y., Gao X. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway. Journal of ethnopharmacology . 2018;211:89–100. - PubMed
-
- Waks A. G., Winer E. P. Breast cancer treatment: a Review. JAMA . 2019;321(3):288–300. - PubMed
-
- Nahta R., O'Regan R. M. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clinical breast cancer . 2010;10 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
